Lineage Cell Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 75
- Market Cap
- $171.3M
- Website
- http://www.lineagecell.com
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
- Conditions
- Spinal Cord Injury CervicalSpinal Cord Injury ThoracicSpinal Cord Injury, AcuteSpinal Cord InjurySpinal Cord Injury, Chronic
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Lineage Cell Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06841770
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
- Conditions
- Spinal Cord Injuries
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Lineage Cell Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05975424
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Shepherd Center, Atlanta, Georgia, United States
LTFU Study of Subjects Who Received GRNOPC1
- Conditions
- Spinal Cord Injuries
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Lineage Cell Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05919563
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Shepherd Center, Atlanta, Georgia, United States
🇺🇸Northwestern Medical Group, Evanston, Illinois, United States
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
- Conditions
- Cervical Spinal Cord InjurySpinal Cord TraumaSpine Injury
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Lineage Cell Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02302157
- Locations
- 🇺🇸
Univ. of California at San Diego, La Jolla, California, United States
🇺🇸Rancho Los Amigos/USC, Los Angeles, California, United States
🇺🇸Stanford University/Santa Clara Valley Medical Center, San Jose, California, United States
Safety Study of GRNOPC1 in Spinal Cord Injury
- Conditions
- Spinal Cord Injury
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Lineage Cell Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01217008
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford University/Santa Clara Valley Medical Center, Palo Alto/San Jose, California, United States
🇺🇸Shepherd Center, Atlanta, Georgia, United States
News
36-Month Results of OpRegen Cell Therapy for Geographic Atrophy to Be Presented at CTS 2025
Long-term 36-month data from the Phase 1/2a trial of RG6501 (OpRegen) for geographic atrophy secondary to AMD will be presented at Clinical Trials at the Summit in June 2025.
Lineage Cell Therapeutics Launches DOSED Study for Novel Spinal Cord Injury Cell Therapy
Lineage Cell Therapeutics has initiated the DOSED clinical study to evaluate OPC1, a stem cell-derived therapy, using a new delivery system for both subacute and chronic spinal cord injury patients.
Emerging Therapies Offer Hope for Geographic Atrophy Treatment
Several therapies are under evaluation in clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), addressing the unmet need for effective treatments.
RG6501 Shows Rapid Improvement in Retinal Structure for Geographic Atrophy Patients
Phase 1/2a trial results for RG6501 (OpRegen) demonstrate significant improvements in outer retinal structure within three months of a single administration in patients with geographic atrophy secondary to AMD.